Trial · NCT03641326
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Greater Than 50% Reduction in Objective Response | Participants With Primary Gliosarcoma | Complete Response | 0 | Participants | |
| Number of Participants With Greater Than 50% Reduction in Objective Response | Participants With Secondary Gliosarcoma | Complete Response | 0 | Participants | |
| Number of Participants With Greater Than 50% Reduction in Objective Response | Participants With Primary Gliosarcoma | Partial Response | 0 | Participants | |
| Number of Participants With Greater Than 50% Reduction in Objective Response | Participants With Secondary Gliosarcoma | Partial Response | 0 | Participants | |
| Number of Participants With 6-month Progression Free Survival (PFS) | Participants With Primary Gliosarcoma | 0 | Participants | ||
| Number of Participants With 6-month Progression Free Survival (PFS) | Participants With Secondary Gliosarcoma | 0 | Participants | ||
| Number of Adverse Events Related to Drug | Participants With Primary Gliosarcoma | 0 | Participants | ||
| Number of Adverse Events Related to Drug | Participants With Secondary Gliosarcoma | 0 | Participants | ||
| Number of Responders and Non-responders With Tumor Markers of Activation | Responders With Primary Gliosarcoma | 0 | Participants | ||
| Number of Responders and Non-responders With Tumor Markers of Activation | Non-Responders With Primary Gliosarcoma | 1 | Participants | ||
| Number of Responders and Non-responders With Tumor Markers of Activation | Responders With Secondary Gliosarcoma | 0 | Participants | ||
| Number of Responders and Non-responders With Tumor Markers of Activation | Non-Responders With Secondary Gliosarcoma | 2 | Participants | ||
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Responders With Primary Gliosarcoma | Baseline | 0 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Non-Responders With Primary Gliosarcoma | Baseline | 2 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Responders With Secondary Gliosarcoma | Baseline | 0 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Non-Responders With Secondary Gliosarcoma | Baseline | 3 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Responders With Primary Gliosarcoma | During Treatment | 0 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Non-Responders With Primary Gliosarcoma | During Treatment | 1 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Responders With Secondary Gliosarcoma | During Treatment | 0 | Participants | |
| Number of Responders and Non-responders With Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) Performed Before and During Treatment With Sunitinib. | Non-Responders With Secondary Gliosarcoma | During Treatment | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03641326/results